Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07441980 | A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05558124 | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | recruiting | Phase 1 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 |
| clinicaltrials |
| NCT06511882 | Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | recruiting | Phase 2 | 37 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437170 | Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML | active not recruiting | Phase 2 | 10 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05580601 | Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 20 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07432100 | Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 20 | Mingfeng ZhaoOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT06773208 | A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05974150 | Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring | recruiting | — | 25 | Carevive Systems, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07425808 | FLT3-ITD Targeted Therapy in Fit AML Patients(FIT-AML) | not yet recruiting | Phase 2 / Phase 3 | 230 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 23, 2026 | clinicaltrials |
| NCT07423104 | A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 24 | University of RochesterOTHER | 0 | Feb 20, 2026 | clinicaltrials |
| NCT02339740 | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | active not recruiting | Phase 3 | 158 | Children's Oncology GroupNETWORK | 6 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07413263 | Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients | not yet recruiting | — | 75 | Assiut UniversityOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07203742 | The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment | recruiting | N/A | 60 | Ege UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04645199 | National Longitudinal Cohort of Hematological Diseases(NICHE) | recruiting | — | 2,300 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06325748 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | active not recruiting | Phase 1 | 21 | Senti BiosciencesINDUSTRY | 2 | Feb 12, 2026 | clinicaltrials |
| NCT07328191 | Quality of Life-Guided Transfusion in Refractory MDS or AML(Q-TRANS) | recruiting | N/A | 52 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407660 | Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax | not yet recruiting | Phase 3 | 250 | Peking University People's HospitalOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT05197426 | A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission | active not recruiting | Phase 2 | 19 | Bristol-Myers SquibbINDUSTRY | 2 | Feb 11, 2026 | clinicaltrials |
| NCT06950034 | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | recruiting | Phase 1 | 105 | Solu Therapeutics, IncINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07130695 | Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation | recruiting | Phase 1 | 15 | Virginia Commonwealth UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07148180 | A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax | recruiting | Phase 1 / Phase 2 | 31 | Jacqueline Garcia, MDOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07172204 | Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML(CHANCE) | recruiting | Phase 2 | 25 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07250217 | Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients(LAMME) | recruiting | N/A | 30 | Groupe Hospitalier de la Region de Mulhouse et Sud AlsaceOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07259707 | Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML(GANCE) | recruiting | Phase 2 | 25 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07386392 | Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia(HYPNO-RV LAM) | not yet recruiting | N/A | 99 | University Hospital, ToulouseOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07383298 | Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase | enrolling by invitation | — | 100 | Qian JiangOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05917405 | Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT(FLUCLORIC) | recruiting | Phase 2 | 302 | Nantes University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05455294 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | active not recruiting | Phase 1 | 16 | Jacqueline Garcia, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07321626 | Romiplostim N01 for Platelet Recovery After Haploidentical HSCT | recruiting | Phase 1 | 130 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03842696 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | active not recruiting | Phase 1 / Phase 2 | 43 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07370064 | Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia(AML CAR-T) | not yet recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07366801 | Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies | recruiting | Phase 2 / Phase 3 | 64 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT06326463 | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | recruiting | Phase 1 | 18 | St. Jude Children's Research HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03701308 | Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | active not recruiting | Phase 2 / Phase 3 | 267 | National Cancer Institute (NCI)NIH | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05001828 | Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia | active not recruiting | Phase 1 | 38 | Polaris GroupINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03987958 | A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)(REVIVE) | active not recruiting | — | 100 | AbbVieINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05143996 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | recruiting | Phase 1 | 60 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06768476 | CART123 + Ruxolitinib in Relapsed/Refractory AML(AML) | active not recruiting | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07347171 | A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies | recruiting | Phase 1 | 45 | Cullgen (Shanghai),IncOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05287568 | CC-486 and Venetoclax for Acute Myeloid Leukemia | recruiting | Phase 1 | 35 | University of Colorado, DenverOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06429449 | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | University of Colorado, DenverOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07342244 | Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | N/A | 18 | Donghua ZhangOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07343687 | Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy . | not yet recruiting | — | 80 | Assiut UniversityOTHER | 0 | Jan 15, 2026 | clinicaltrials |
| NCT05942599 | Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation(CARAML) | active not recruiting | Phase 1 | 10 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06572982 | Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients | active not recruiting | N/A | 20 | Hikma Pharmaceuticals LLCINDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03121014 | Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes | active not recruiting | Phase 2 | 38 | University of Illinois at ChicagoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05317403 | Venetoclax to Augment Epigenetic Modification and Chemotherapy | recruiting | Phase 1 | 40 | Medical College of WisconsinOTHER | 1 | Jan 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 2, 2026source: clinicaltrials